|
Market Closed -
London S.E.
11:35:09 2026-09-10 am EDT
|
5-day change | 1st Jan Change | ||
| 1,775.50 GBX | -1.55% |
|
-4.62% | -2.69% |
| Sep. 10 | GSK gets Japan approval for prefilled Shingrix vaccine | AN |
| Sep. 10 | GSK Gets Japan Approval for Prefilled Shingrix Syringe | MT |
| Market Cap | 71.14B 96.11B 82.76B 78.15B 133B 9,171B 134B 931B 358B 4,666B 361B 353B 14,850B | P/E 2026 * |
13.5x | P/E 2027 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise Value | 91.87B 124B 107B 101B 172B 11,842B 173B 1,202B 462B 6,025B 466B 456B 19,175B | EV / Sales 2026 * |
2.71x | EV / Sales 2027 * | 2.51x |
| Free-Float |
92.75% | Yield 2026 * |
3.92% | Yield 2027 * | 4.22% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
OTC Markets
| GLAXF | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript : GSK plc
| 1 day | -1.55% | ||
| 1 week | -4.62% | ||
| Current month | -4.21% | ||
| 1 month | -9.44% | ||
| 3 months | -6.72% | ||
| 6 months | -13.22% | ||
| Current year | -2.69% |
| 1 week | 1,772 |  | 1,885.5 |
| 1 month | 1,772 | | 1,948.5 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,455 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/24/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -28,978 | 0.0007% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -49 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.55% | -4.62% | +19.08% | +22.94% | 97.89B | |
| -0.11% | -3.20% | +49.61% | +91.49% | 1,002B | |
| -0.27% | -3.22% | +50.51% | +65.89% | 644B | |
| +1.63% | -2.57% | +21.19% | +71.12% | 443B | |
| -0.63% | -1.06% | +28.11% | +34.59% | 343B | |
| +0.43% | -14.61% | +9.88% | +27.26% | 262B | |
| +0.93% | -1.82% | -1.82% | +8.41% | 245B | |
| -2.25% | -13.63% | +36.61% | +47.43% | 212B | |
| -0.90% | -5.09% | -15.47% | -57.75% | 199B | |
| -0.58% | -3.21% | +25.10% | +90.54% | 181B | |
| Average | +0.05% | -4.81% | +22.28% | +40.19% | 362.76B | |
| Weighted average by Cap. | +0.38% | -4.21% | +31.56% | +56.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.95B 45.86B 39.49B 37.29B 63.45B 4,376B 64.05B 444B 171B 2,226B 172B 168B 7,086B | 35.49B 47.94B 41.28B 38.99B 66.34B 4,575B 66.96B 464B 179B 2,328B 180B 176B 7,408B |
| Net income | 5.38B 7.27B 6.26B 5.91B 10.06B 694B 10.15B 70.38B 27.08B 353B 27.27B 26.7B 1,123B | 6.37B 8.61B 7.41B 7B 11.91B 822B 12.03B 83.38B 32.08B 418B 32.31B 31.63B 1,330B |
| Net Debt | 20.72B 27.99B 24.1B 22.76B 38.73B 2,671B 39.09B 271B 104B 1,359B 105B 103B 4,325B | 17.98B 24.3B 20.92B 19.76B 33.62B 2,318B 33.93B 235B 90.51B 1,179B 91.17B 89.24B 3,754B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-10 | GBX 1,775.50 | -1.55% | 3,018,902 |
| 26-09-09 | GBX 1,803.50 | +0.39% | 3,659,863 |
| 26-09-08 | GBX 1,796.50 | -2.23% | 5,350,556 |
| 26-09-07 | GBX 1,837.50 | -0.49% | 4,623,292 |
| 26-09-04 | GBX 1,846.50 | -1.07% | 3,782,887 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
